Matrix metalloproteinase-3 gene promoter polymorphisms: A potential risk factor for pelvic organ prolapse

Charalampos Karachalios1, Panagiotis Bakas1, Georgios Kaparos2

  • 1Second Department of Obstetrics and Gynecology, Aretaieio University Hospital, National and Kapodistrian University of Athens, Medical School, Athens 11528, Greece.

Biomedical Reports
|September 3, 2016
PubMed

Insights

Single-nucleotide polymorphisms (SNPs) in the MMP-3 gene promoter were investigated for their association with pelvic organ prolapse (POP). The study found no significant difference in MMP-3 gene promoter variants between women with and without POP, suggesting SNPs alone do not increase genetic susceptibility.

Area of Science:

  • Genetics
  • Biochemistry
  • Gynecology

Background:

  • Pelvic organ prolapse (POP) is a common condition affecting connective tissue integrity.
  • Matrix metalloproteinases (MMPs) degrade connective tissues; their activity can be influenced by genetic variations.
  • Single-nucleotide polymorphisms (SNPs) in MMP genes, such as MMP-3, may impact pelvic floor support.

Purpose of the Study:

  • To investigate the association between MMP-3 gene promoter single-nucleotide polymorphisms (SNPs) and the risk of developing pelvic organ prolapse (POP).

Main Methods:

  • Genotyping of MMP-3 gene promoter variants (5A/6A) using quantitative polymerase chain reaction (PCR) in 80 women with POP and 80 controls.
  • Analysis of SNP detection via sequence-specific hybridization probe-binding assays and melting curve analysis.

Main Results:

  • No statistically significant difference was observed in the distribution of MMP-3 gene promoter variants (5A/5A, 5A/6A, 6A/6A) between the POP patient group and the control group (P=0.4758).

Conclusions:

  • MMP-3 gene promoter single-nucleotide polymorphisms (SNPs) alone are insufficient to confer increased genetic susceptibility to pelvic organ prolapse (POP).
  • Further research may be needed to explore other genetic or environmental factors contributing to POP development.

Related Concept Videos

Mitral Valve Prolapse III: Nursing Management01:19

Mitral Valve Prolapse III: Nursing Management

The nursing management of Mitral Valve Prolapse, or MVP, centers around patient education, symptom monitoring, and lifestyle modifications.Patient Education on MVP Diagnosis and Heredity: Nurses should provide comprehensive education about MVP, a condition where the mitral valve does not close appropriately during heartbeats. This education often includes the condition's pathophysiology, symptoms, and potential complications, like arrhythmias or mitral regurgitation. Though not fully...
505
Role of Matrix Metalloproteases in Degradation of ECM01:23

Role of Matrix Metalloproteases in Degradation of ECM

Matrix metalloproteases (MMPs) are enzymes involved in the hydrolysis of proteins and glycoproteins of the extracellular matrix. MMPs are essential for the migration and proliferation of cells through the dense matrix network, throughout embryonic development, and throughout morphogenesis. The first MMP activity discovered was a collagenase in a tadpole's tail undergoing metamorphosis. The active collagen deposition and modifications lead to the morphogenesis of tadpoles into the adult...
3.6K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
94